Inpharma Weekly

, Volume 1167, Issue 1, pp 19–19 | Cite as

Idarubicin preferred to daunorubicin as AML induction therapy

Newsletter Article
  • 2 Downloads

Keywords

Complete Remission Myeloid Leukaemia British Journal Anthracyclines Cytarabine 

Copyright information

© Adis International Ltd 1998

Personalised recommendations